Viracta Therapeutics' NAVAL-1 Trial Achieves Efficacy Threshold For Expansion In Relapsed Or Refractory EBV-Positive Peripheral T-Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Viracta Therapeutics, Inc. (NASDAQ:VIRX) announced that its NAVAL-1 clinical trial for the treatment of relapsed or refractory EBV+ peripheral T-cell lymphoma has met the pre-specified efficacy threshold for expansion into Stage 2. The threshold is based on a minimum number of objective responses achieved within the first 10 patients enrolled.
June 28, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viracta Therapeutics' NAVAL-1 trial has met the efficacy threshold for expansion into Stage 2, indicating positive progress in the company's clinical development.
The news indicates that Viracta Therapeutics' NAVAL-1 trial has achieved its pre-specified efficacy threshold, allowing it to move into the next stage of the study. This is a positive development for the company and could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100